DLT, dose-limiting toxicity; DSMC, Data Safety Monitoring Committee; NMIBC, non-muscle-invasive bladder cancer.
DLT, dose-limiting toxicity; DSMC, Data Safety Monitoring Committee; HNSCC, head and neck squamous cell cancer; MIBC, muscle-invasive bladder cancer.
LUMINOS-103 (NCT04690699) is a multicenter, open-label, single-arm phase 1/2 basket study designed to enable investigation of the efficacy and safety of lerapolturev in several solid tumor types. The study is currently investigating the ability of intravesicular lerapolturev monotherapy to successfully infect cancerous bladder tissue among patients with low-intermediate risk NMIBC undergoing planned transurethral resection of bladder tumor (TURBT) or cystectomy.
Please contact us or email [email protected].